title: Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome.
abstract: Fragile X syndrome (FXS) is the most common form of inherited intellectual disability and autism. The protein (FMRP) encoded by the fragile X mental retardation gene (FMR1), is an RNA-binding protein linked to translational control. Recently, in the Fmr1 knockout mouse model of FXS, dysregulated translation initiation signaling was observed. To investigate whether an altered signaling was also a feature of subjects with FXS compared to typical developing controls, we isolated total RNA and translational control proteins from lymphocytes of subjects from both groups (38 FXS and 14 TD). Although we did not observe any difference in the expression level of messenger RNAs (mRNAs) for translational initiation control proteins isolated from participant with FXS, we found increased phosphorylation of the mammalian target of rapamycin (mTOR) substrate, p70 ribosomal subunit 6 kinase1 (S6K1) and of the mTOR regulator, the serine/threonine protein kinase (Akt), in their protein lysates. In addition, we observed increased phosphorylation of the cap binding protein eukaryotic initiation factor 4E (eIF4E) suggesting that protein synthesis is upregulated in FXS. Similar to the findings in lymphocytes, we observed increased phosphorylation of S6K1 in brain tissue from patients with FXS (n = 4) compared to normal age-matched controls (n = 4). Finally, we detected increased expression of the cytoplasmic FMR1-interacting protein 2 (CYFIP2), a known FMRP interactor. This data verify and extend previous findings using lymphocytes for studies of neuropsychiatric disorders and provide evidence that misregulation of mTOR signaling observed in the FXS mouse model also occurs in human FXS and may provide useful biomarkers for designing targeted treatments in FXS.
authors.affiliation: Center for Neural Science, New York University, New York, NY, USA.
authors.forename: C A
authors.initials: CA
authors.lastname: Hoeffer
authors.forename: E
authors.initials: E
authors.lastname: Sanchez
authors.forename: R J
authors.initials: RJ
authors.lastname: Hagerman
authors.forename: Y
authors.initials: Y
authors.lastname: Mu
authors.forename: D V
authors.initials: DV
authors.lastname: Nguyen
authors.forename: H
authors.initials: H
authors.lastname: Wong
authors.forename: A M
authors.initials: AM
authors.lastname: Whelan
authors.forename: R S
authors.initials: RS
authors.lastname: Zukin
authors.forename: E
authors.initials: E
authors.lastname: Klann
authors.forename: F
authors.initials: F
authors.lastname: Tassone
mesh_terms: D048868:Adaptor Proteins, Signal Transducing / Q000096:biosynthesis* / Q000235:genetics; D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005260:Female; D051860:Fragile X Messenger Ribonucleoprotein 1 / Q000235:genetics / Q000378:metabolism; D005600:Fragile X Syndrome / Q000235:genetics / Q000378:metabolism*; D005786:Gene Expression Regulation / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D061251:Primary Cell Culture; D015398:Signal Transduction / Q000502:physiology*; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology; D015854:Up-Regulation / Q000502:physiology*; D055815:Young Adult
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D051860:Fragile X Messenger Ribonucleoprotein 1; D058570:TOR Serine-Threonine Kinases; C518673:CYFIP2 protein, human; C497683:FMR1 protein, human; C546842:MTOR protein, human